Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51

Background: Bleomycin, a potent antitumor agent, is limited in clinical use due to the potential for fatal pulmonary toxicity. The accelerated DNA damage and senescence in alveolar epithelial cells (AECs) is considered a key factor in the development of lung pathology. Understanding the mechanisms for bleomycin-induced lung injury is crucial for mitigating its adverse effects.

Methods: Human lung epithelial (A549) cells were exposed to bleomycin and subsequently assessed for cellular senescence, DNA damage, and double-strand break (DSB) repair. The impact of RAD51 overexpression on DSB repair and senescence in AECs was evaluated in vitro. Additionally, bleomycin was intratracheally administered in C57BL/6 mice to establish a pulmonary fibrosis model.

Results: Bleomycin exposure induced dose- and time-dependent accumulation of senescence hallmarks and DNA lesions in AECs. These effects are probably due to the inhibition of RAD51 expression, consequently suppressing homologous recombination (HR) repair. Mechanistic studies revealed that bleomycin-mediated transcriptional inhibition of RAD51 might primarily result from E2F1 depletion. Furthermore, the genetic supplement of RAD51 substantially mitigated bleomycin-mediated effects on DSB repair and senescence in AECs. Notably, decreased RAD51 expression was also observed in the bleomycin-induced mouse pulmonary fibrosis model.

Conclusions: Our works suggest that the inhibition of RAD51 plays a pivotal role in bleomycin-induced AECs senescence and lung injury, offering potential strategies to alleviate the pulmonary toxicity of bleomycin.

Bleomycin; Homologous recombination; Lung injury; Rad51; Senescence.